Horizontal acquisition of the Type I restriction–modification system enhances bacterial pathogenicity by mediating methylation of transcription factor-encoding genes
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Jiayue Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Life and Health Sciences, Hainan Province Key Laboratory of One Health, Collaborative Innovation Center of Life and Health, Hainan Universi…. Hauptthemen laut MEDLINE: DNA Methylation, Transcription Factors, Gene Transfer, Horizontal, DNA Restriction-Modification Enzymes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Hainan Provincial Natural Science Foundation, Hainan Province Science and Technology Special Fund.
Abstract (Originalsprache)
The Type I restriction–modification (RM) system, encoded by the hsdR, hsdM, and hsdS genes, plays a crucial role in shaping the prokaryotic DNA methylation landscape. Although known for defending against foreign DNA, key aspects of its evolutionary trajectory and functional implications after stable inheritance remain poorly understood. In this study, we identified four primary types of Type I RM systems across 4273 prokaryotic genomes based on gene arrangement. Among these, the 5′-hsdR, hsdM, hsdS-3′ (RMS) configuration emerged as the most evolutionarily advanced form. Phylogenetic reconstruction revealed that RMS was formed through gene duplication, horizontal gene transfer, and gene loss, and it now stably exists in bacteria. Functional characterization demonstrated that RMS deletion in bacteria led to the absence of flagella and a significant reduction in their ability to colonize and infect mice. Integrated multi-omics analysis uncovered a potential regulatory cascade where RMS modulates the expression of transcription factors via DNA methylation, which in turn regulate downstream flagellar and chemotaxis genes, thereby influencing bacterial pathogenicity. These findings establish a complete evolutionary–functional paradigm, elucidating how (evolutionary trajectory) and why (functional constraints) RMS has been stably inherited in bacterial genomes, and revealing the molecular mechanism through which RMS orchestrates bacterial pathogenicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Life and Health Sciences, Hainan Province Key Laboratory of One Health, Collaborative Innovation Center of Life and Health, Hainan University, Haikou, Hainan 570228, China.
- Faculty of Animal Science and Technology, Key Laboratory of Animal Nutrition and Feed Science of Yunnan Province, Yunnan Agricultural University, Kunming, Yunnan 650201, China.
ORCID-Profile: Hong Li
Förderung
- National Natural Science Foundation of China
- Hainan Provincial Natural Science Foundation
- Hainan Province Science and Technology Special Fund
Zitieren
APA
Ma, J., Jiang, X., Bi, H., Li, J., Ma, X., Chi, X., Tang, Y., Liu, Z., & Li, H. (2025). Horizontal acquisition of the Type I restriction–modification system enhances bacterial pathogenicity by mediating methylation of transcription factor-encoding genes. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf659
Vancouver
Ma J, Jiang X, Bi H, Li J, Ma X, Chi X, et al. Horizontal acquisition of the Type I restriction–modification system enhances bacterial pathogenicity by mediating methylation of transcription factor-encoding genes. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf659
BibTeX
@article{Ma2025,
author = {Ma, Jiayue and Jiang, Xiaoli and Bi, Haixin and Li, Juanjuan and Ma, Xiang and Chi, Xue and Tang, Yanqiong and Liu, Zhu and Li, Hong},
title = {Horizontal acquisition of the Type I restriction–modification system enhances bacterial pathogenicity by mediating methylation of transcription factor-encoding genes},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf659}
}
EUVIMED